Skip to main content
GOSS logo

GOSS · Gossamer Bio, Inc.

Track GOSS — free
$11.16 -0.27 (-2.36%)
Market Cap
$68.69M
Shares
6.12M
Volume · Nov 19 143.82K Avg daily vol (50 sessions) 251.05K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.23 Open$11.24 Day$10.80–11.85 52W close$8.43–303.20 Avg vol 30d198K Short int1.3M · 21.9% of shares · 7.5d Short vol21% Last earningsJul 27, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 10

Up next

Oct 15, 2027 Est · unconfirmed · in 47 wks

Latest documents

2026
Nov 16
Registration statement S-3
Selling holders register resale of 1,697,363 warrant shares

Gossamer Bio, Inc. registered up to 1,697,363 common shares issuable upon exercise of warrants issued in the June 4, 2026 early settlement of its 5.00% Convertible Senior Notes due 2027; the company will receive no sale proceeds.

Read from the first part of this long document
3 source passages
GOSSAMER BIO, INC. This prospectus relates to the proposed resale or other disposition by the selling securityholders identified in this prospectus, including their transferees, pledgees, donees or successors, of up to 1,697,363 shares of our common stock, par value $0.0001 per share issuable upon the exercise of warrants to acquire shares of common stock. The warrants were issued to eligible holders of our outstanding 5.00% Convertible Senior Notes due 2027 in connection with an exchange offer, the early settlement of which occurred on June 4, 2026, or the Exchange Offer. We are not selling any shares of common stock under this prospectus and will not receive any of the proceeds from the sale or other disposition of common stock by the selling securityholders. Open the document at this passage
Nov 10
Current report 8-K
Seralutinib NDA submitted; cash totals $51.2 million

Gossamer Bio submitted its first Seralutinib NDA to the FDA in September 2026; cash, cash equivalents and marketable securities totaled $51.2 million as of September 30, 2026, and quarterly net loss was $48.1 million.

Financial results
4 source passages
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update Gossamer submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatment of PAH. Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities totaled $51.2 million as of September 30, 2026, compared to $57.0 million as of June 30, 2026. Net Loss: Net loss for the quarter ended September 30, 2026, was $48.1 million, or $7.36 per share, compared to a net loss of $48.2 million, or $16.92 per share, for the same period in 2025. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Seralutinib NDA submitted after Chiesi rights reacquisition

Gossamer Bio, Inc. reacquired worldwide seralutinib rights from Chiesi in July 2026 and submitted an NDA for PAH in September 2026. It had $51.2 million in cash, cash equivalents and marketable securities as of September 30, 2026.

Revenue $38.43M ▲ 189.1% Net loss $48.07M Diluted EPS -$7.36
Read from the MD&A section
3 source passages
In July 2026, we entered into the Rights Reacquisition Agreement with Chiesi, pursuant to which we reacquired worldwide development and commercial rights to seralutinib. Following a Pre-NDA Type B meeting with the FDA held in mid-June 2026 and receipt of the official meeting minutes, we submitted an NDA for seralutinib for the treatment of PAH in September 2026. As of September 30, 2026, we had $51.2 million in cash, cash equivalents and marketable securities. Open the document at this passage
Oct 28
Current report 8-K Events of Oct 27
Stockholders approve share issuance above 20% tied to August 2026 financing

Gossamer Bio stockholders approved, at an October 27, 2026 special meeting, issuing common stock under the August 20, 2026 Securities Purchase Agreement that would exceed 20% of outstanding shares. Votes: 2,808,000 for, 37,814 against, 29,441 abstaining.

Shareholder vote results
5 source passages
The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27, 2026 The approval, in accordance with Nasdaq Listing Rules 5635(c) and 5635(d), of the potential issuance of shares of the Company's common stock, par value $0.0001 per share (the “Common Stock”), pursuant to the Securities Purchase Agreement, dated August 20, 2026 which issuances of Common Stock would, in the aggregate, exceed 20% of the number of shares of Common Stock issued and outstanding immediately prior to the Initial Closing For | Against | Abstain | Broker Non-Votes 2,808,000 | 37,814 | 29,441 | - Open the document at this passage
Sep 28
Current report 8-K Events of Sep 25
Other events

On September 25, 2026, Gossamer Bio received Nasdaq notice that it regained compliance with the minimum bid price requirement, closing the matter. The company effected a 1-for-80 reverse stock split on September 10, 2026, and split-adjusted trading began on September 11, 2026.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$78.42M
Trailing 12 months
Net income (TTM)
−$125.07M
Trailing 12 months
Revenue growth YoY
+189.1%
Year over year
Operating margin
-140.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-223.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+129.1%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
21.9%
Latest settlement · 7.5 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 27, 2026
Q2 FY26

TL;DR. Gossamer announced a clear regulatory path for its planned September 2026 NDA submission for seralutinib in PAH after FDA characterized efficacy concerns as review issues rather than filing issues, reacquired worldwide rights from Chiesi in exchange for a capped royalty and milestones, and completed a convertible note exchange that reduced debt by approximately $115.9 million, leaving approximately $57 million in cash as of June 30, 2026.

Bullish
  • + FDA Pre-NDA feedback frames PROSERA efficacy concerns as review issues rather than filing issues, clearing a path to September 2026 NDA submission and potential Q3 2027 approval decision.
  • + Gossamer reacquired worldwide rights to seralutinib from Chiesi with no upfront cash payment and received a $5 million payment from Chiesi, retaining the substantial majority of global economics.
  • + Convertible note exchange reduced aggregate debt principal by approximately $115.9 million and lowered outstanding 2027 Notes to approximately $18.9 million.
Bearish
  • − FDA has not yet accepted the planned NDA for filing or completed substantive review, and approvability remains uncertain.
  • − Company had only approximately $57 million in cash as of June 30, 2026, which may be insufficient to fund a full commercial launch without additional capital.
  • − Future performance is entirely dependent on the success of seralutinib, creating concentration risk.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −59%
below
Price vs 50-day avg +8%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +19%
trailing
6-month return −29%
trailing
YTD return −95%
this year
Relative strength −23%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $10 › 200d $28 — 200d above 50d
Institutional flow Distributing
-55% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
21.90% of shares out · ▼ -6.8% MoM · 7.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
79 holders — near 3-yr low, contrarian setup
Squeeze score 77
high risk · 0–100
Fundamentals
Weak
Revenue growth −58%
Y/Y
EPS growth −200%
Y/Y
Free cash flow $-171.3M
Balance sheet $46.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 140%
annualized · 1-yr
Max drawdown −97%
past year
ATR 9.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Mar 3, 2022
Improvement in PVR from baseline · week 24 of the TORREY study 18% – 32%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−59% Bearish
Price vs 50-day avg
+8% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $10 › 200d $28 — 200d above 50d
Institutional flow Distributing
-55% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
21.90% of shares out · ▼ -6.8% MoM · 7.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
79 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $8 Now $11 · 1% Range high $303
vs 200-day avg -59% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, Cash Equivalents and Marketable Securities $51.2M as of September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GOSS
Gossamer Bio, Inc.
this stock
$68.69M — -57.7% — 21.9%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
79
% held
64.6%
Net QoQ
-678.6K sh
Top holder
683 Capital Management, L…
Held Float
View
Held by Funds
Fund positions
35
View
Short & Settlement
Short Interest Falling
Shares short
1.3M
Days to cover
7.5d
Change
-97.0K sh
View
Short Volume
Short vol %
21%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
7.5K
Value
$80.4K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
43.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$48.5M
Net income (FY)
$-170.4M
EPS diluted
$-60.00
View
Filings
SEC Filings
Latest
S-3
Filed
Nov 16, 2026
This year
36

Gossamer Bio, Inc. registered up to 1,697,363 common shares issuable upon exercise of warrants issued in the June 4, 2026 early settlement of its 5.00% Convertible Senior Notes due 2027; the company will receive no sale proceeds.

View
Exempt Offerings
Offering
$150.0M
Filed
Sep 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Jul 27, 2026
View
Investor Relations
Latest news
Gossamer Bio Announces Third Quar…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
GOSS -0.1% +18.7% -29.1% +8.2% -95.5%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +5.4% +25.0% -23.5% +13.5% -100.5%
Key facts CIK 1728117 CUSIP 38341P201 13F (30d) 100 filings 75 filers Visit website Investor relations